Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive ...
Dr Ryotaro Nakamura - City of Hope, California, USA
Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive care in older patients with advanced MDS ( Dr Ryotaro Nakamura - City of Hope, California, USA )
17 Feb 2021
OncoAlert and ecancer weekly roundup for February 01 - 06, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for February 01 - 06, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
9 Feb 2021
Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China
Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China
Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China ( Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China )
29 Jan 2021
OncoAlert and ecancer weekly roundup for January 11 - 17, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for January 11 - 17, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
21 Jan 2021
Haematology updates from SIOG 2020
Dr Tanya Wildes - SIOG Science & Education Committee Chair
Haematology updates from SIOG 2020 ( Dr Tanya Wildes - SIOG Science & Education Committee Chair )
13 Jan 2021
The Burkitt lymphoma international prognostic index
Prof Adam Olszewski - Brown University, Providence, USA
The Burkitt lymphoma international prognostic index ( Prof Adam Olszewski - Brown University, Providence, USA )
24 Dec 2020
OncoAlert Colloquium Day 4: Gynae-oncology, lymphoma, sarcoma and melanoma
Dr Dizon, Dr Trent, Dr Cordoba, Dr Rolfo, Dr Haanen
OncoAlert Colloquium Day 4: Gynae-oncology, lymphoma, sarcoma and melanoma ( Dr Dizon, Dr Trent, Dr Cordoba, Dr Rolfo, Dr Haanen )
23 Dec 2020
Results of venetoclax and azacitidine combination in chemotherapy ineligible unt...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with AML ( Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA )
22 Dec 2020
Long-term follow-up of low-intensity chemotherapy with combination therapy for r...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute lymphoblastic leukaemia patients ( Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA )
22 Dec 2020
Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumu...
Prof Evangelos Terpos - University of Athens, Athens, Greece
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and bortezomib ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020